New pill hopes to boost immune system against tough cancers
NCT ID NCT05614102
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 34 times
Summary
This early-stage study tests a new drug, BAY 2965501, that aims to activate the body's immune T-cells to fight advanced solid tumors (like certain skin, kidney, stomach, and lung cancers). The study involves about 284 participants and will test the drug alone or combined with other treatments. The main goals are to check safety, find the best dose, and see how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital | Oncology Department
Antwerp, 2650, Belgium
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, 518172, China
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, 100000, China
-
Clinica Universidad De Navarra | Madrid | Oncologia
Madrid, 28027, Spain
-
Clinica Universidad De Navarra | Pamplona | Oncologia
Pamplona, Madrid, 31008, Spain
-
Freeman Hospital
Newcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
-
Ghent University Hospital | Drug Research Unit Department
Ghent, 9000, Belgium
-
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
London, Greater London, SE1 9RT, United Kingdom
-
Hospital Hm Nou Delfos | Oncologia
Barcelona, 08023, Spain
-
Hospital Universitari Vall D Hebron | Oncologia
Barcelona, 08035, Spain
-
Hospital Universitario Hm Sanchinarro | Oncologia
Madrid, 28050, Spain
-
National Cancer Center Hospital East
Kashiwa, Chiba, 277-8577, Japan
-
Oxford University Hospitals NHS Foundation Trust | Churchill Hospital - Oncology
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
Royal Marsden NHS Trust (Surrey)
Sutton, Surrey, SM2 5PT, United Kingdom
-
START | San Antonio
San Antonio, Texas, 78229, United States
-
Samsung Medical Center - Oncology Department
Seoul, 135-710, South Korea
-
Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
Denver, Colorado, 80218, United States
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggido, 13620, South Korea
-
Severance Hospital, Yonsei University Health System - Oncology Department
Seoul, Seoul Teugbyeolsi, 03722, South Korea
-
Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
Hangzhou, Zhejiang, 310016, China
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.